Stocktoria
Protara Therapeutics, Inc. TARA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2014-10-22
Protara Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $42.6M | $31.7M | $25.0M | $16.8M | $21.1M |
| Operating income | -$64.5M | -$49.2M | -$43.6M | -$67.1M | -$47.5M |
| Interest expense | — | — | — | — | $0 |
| Net income | -$57.4M | -$44.6M | -$40.4M | -$66.0M | -$47.3M |
| EPS (diluted) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 |
| Operating cash flow | -$56.4M | -$35.8M | -$37.6M | -$26.5M | -$34.5M |
| Free cash flow | -$56.5M | -$35.9M | -$37.6M | -$26.6M | -$35.1M |
| Cash & equivalents | $49.7M | $162.8M | $39.6M | $24.1M | $35.7M |
| Total assets | $209.5M | $181.5M | $79.0M | $113.3M | $172.6M |
| Total liabilities | $13.1M | $14.3M | $10.6M | $11.2M | $10.7M |
| Shareholders' equity | $196.4M | $167.1M | $68.3M | $102.1M | $161.9M |
Source: SEC EDGAR filings · CIK 0001359931 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.